← All trials
NCT03091192
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 17, 2017
- Primary completion
- Feb 19, 2021
- Completion date
- Feb 19, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 180
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Hutchison MediPharmaCollaborator
- Harvard UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.